Trial Profile
An open, randomised, parallel group, multicentre study to compare the efficacy and safety of Flutiform pMDI vs Fluticasone pMDI Plus Formoterol DPI in adolescent and adult subjects with mild to moderate-severe persistent, reversible asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Formoterol/fluticasone propionate (Primary) ; Fluticasone propionate; Formoterol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Mundipharma Research
- 07 Aug 2012 Additional location (Belgium) added as reported by European Clinical Trials Database.
- 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
- 22 Jul 2008 The primary endpoint has been met, according to a SkyePharma media release.